Aquestive Therapeutics, Inc. Deferred Tax Assets, Deferred Income
Aquestive Therapeutics, Inc. (AQST) had Deferred Tax Assets, Deferred Income of $5.14 million as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2026-03-04
- 2025-12-31: Deferred Tax Assets, Deferred Income $5.14M.
- 2024-12-31: Deferred Tax Assets, Deferred Income $5.16M.
- 2023-12-31: Deferred Tax Assets, Deferred Income $7.66M.
- 2022-12-31: Deferred Tax Assets, Deferred Income $2.33M.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2025-12-31 | $5.14M 10-K · filed 2026-03-04 |
| 2024-12-31 | $5.16M 10-K · filed 2026-03-04 |
| 2023-12-31 | $7.66M 10-K · filed 2025-03-05 |
| 2022-12-31 | $2.33M 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |